SLC5A2 and bacterial urinary tract infection: While this study contributes to the growing body of evidence, future multicenter studies are crucial to comprehensively assess the long-term effects and further strengthen our understanding of the relationship between SGLT2 inhibitors and UTI risk in patients with diabetes.